We then quantified by IHC analysis the number and activity of CD8+ T cells in both cancer models, 4NQO-L and 4NQO-T, after a SE of 5–10 days or a PE of 25–35 days of treatment with trametinib. This evidence concerns the gene CD8A and cancer.